

1 **Pregnancy and breastfeeding during COVID-19 pandemic: A systematic review of**
2 **published pregnancy cases**

3

4 **Authors**

5 Carina Rodrigues^{*¥1}, Inês Baía^{¥1}, Rosa Domingues², Henrique Barros^{1,3}

6

7 **Affiliations**

8 ¹ EPIUnit – Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal.

9 ² Instituto Nacional de Infectologia Evandro Chagas / Fundação Oswaldo Cruz, Rio de
10 Janeiro, Brasil

11 ³ Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade
12 de Medicina, Universidade do Porto, Porto, Portugal.

13

14 [¥] Equal contribution

15

16 **Corresponding author**

17 Carina Rodrigues

18 Instituto de Saúde Pública da Universidade do Porto

19 Rua das Taipas, 135, 4050-600 Porto, Portugal

20 E-mail: carina.rodrigues@ispup.up.pt

21 Phone: (+351) 222061820

22

23 **Word count abstract: 245**

24 **Word count main text: 2752**

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Abstract**

27 **Background:** The COVID-19 pandemic is an emerging concern regarding the potential
28 adverse effects during pregnancy. This study reviews knowledge on the impact of
29 COVID-19 on pregnancy and describes the outcome of published cases of pregnant
30 women diagnosed with COVID-19.

31 **Methods:** Searches were conducted in PubMed® up to 8 April 2020, using PRISMA
32 standards, to identify original published studies describing pregnant women at any
33 gestational age diagnosed COVID-19. There were no date or language restrictions on the
34 search. All identified studies were included irrespective of assumptions on study quality.

35 **Results:** We identified 30 original studies reporting 212 cases of pregnant women with
36 COVID-19 (30 discharged while pregnant), 200 from China and 12 from other countries.
37 The 182 published deliveries resulted in one stillbirth and 185 live births. Four women
38 with severe COVID-19 required admission to an intensive care unit but no cases of
39 maternal death were reported. There was one neonatal death. Preterm births occurred in
40 28.7% of cases, but it is unclear whether this was iatrogenic. All cases with amniotic fluid,
41 placenta, and/or cord blood analyzed for the SARS-CoV-2 virus were negative. Four
42 newborns were positive for SARS-CoV-2 and three newborns had high levels of IgM
43 antibodies. Breast milk samples from 13 mothers and described in seven studies showed
44 no evidence of SARS-CoV-2.

45 **Conclusion:** The evidence related to the effect of COVID-19 on pregnant women is still
46 limited. Pregnant women and newborns should be considered particularly vulnerable
47 populations regarding COVID-19 prevention and management strategies.

48

49 **Keywords:** COVID-19, SARS-COV-2, Pregnancy, Vertical transmission, Breastfeeding,
50 Perinatal outcomes, systematic review.

51 **Introduction**

52 The disease resulting from infection with the Severe Acute Respiratory Syndrome
53 Coronavirus 2 (SARS-COV-2) and designated COVID-19 by the World Health
54 Organization (WHO) was first identified in humans in December 2019, in the city of
55 Wuhan, China,¹ and can present from asymptomatic to a severe acute respiratory infection
56 requiring intensive care.^{2, 3} The infection can occur at any age, but COVID-19 is
57 proportionally uncommon in children (<1% of the total cases). The infection fatality rate
58 is around 1% but much higher in older people or those with pre-existing medical
59 conditions (such as heart disease, diabetes, COPD).^{2, 4}

60 Person-to-person transmission of COVID-19 is well established and can occur when an
61 infected person coughs, sneezes or speaks and scattered droplets are inhaled or reach the
62 mucous membranes of the mouth, nose or eyes of susceptible. COVID-19 can also be
63 transmitted through direct hand contact with surfaces or objects contaminated with
64 SARS-CoV-2 followed by contact with the mouth, nose or eyes.²

65 Pregnant women and newborns receive special attention and there is an emerging concern
66 with the potential risk of SARS-COV-2 vertical transmission (from mother to fetus) or
67 associated malformations, and contagion during delivery and breastfeeding; likewise, it
68 is important to determine the potential adverse effects of COVID-19 in pregnant women.⁵⁻

69 ⁸ However, in general, the available information remains scarce.

70 This study reviews published cases of pregnant women diagnosed with COVID-19.

71

72 **Methods**

73 The review follows the Preferred Reporting of Systematic Reviews and Meta-Analysis
74 (PRISMA) guidelines.^{9, 10}

75 We searched PubMed® up to 8 April 2020 to identify original published studies
76 describing pregnant women at any gestational age diagnosed with COVID-19 (confirmed
77 by clinical/radiological evidence of pneumonia compatible with SARS-CoV-2 and/or by
78 quantitative real-time polymerase chain reaction (PCR) or dual fluorescence PCR of
79 SARS-CoV-2 infection). The following search expression was used [(COVID-19 OR
80 2019-nCoV OR "novel coronavirus" OR SARS-CoV-2 OR "coronavirus 2") AND
81 (pregnancy OR delivery OR pregnant OR obstetric* OR maternal OR perinatal OR
82 breastfeeding)]. Also, reference tracking was carried out to identify other potential studies
83 to be included.

84 Each reference retrieved was screened independently by two researchers (IB and RD)
85 following predefined criteria to determine eligibility for the systematic review. Studies
86 were excluded if: (1) did not involve humans (e.g. in vitro or animal research); (2) non-
87 original articles (e.g. book chapters, review articles, editorials, comments, guidelines); (3)
88 data not reporting pregnant women diagnosed with COVID-19; and (4) duplicate studies
89 or evaluating the same sample. There were no date or language restrictions on the search.

90 Two researchers (IB and RD) reviewed the included studies and extracted the following
91 data: collection period, maternal age, pregnancy complications, type of delivery,
92 indication for cesarean section, gestational age at birth (or at admission), pregnancy
93 outcome, maternal admission to intensive care unit, maternal death, neonatal outcomes
94 (birth weight, Apgar at 1 and 5 minutes, neonatal complications, breastfeeding),
95 intrauterine and/or neonatal samples collected for detection of SARS-CoV-2 (such as
96 amniotic fluid, cord blood, placenta, breast milk, nasopharyngeal and anal swabs) and
97 their results (negative/positive).

98 All identified original studies reporting cases of pregnant women at any gestational age
99 diagnosed with COVID-19 were included irrespective of study quality. Cases reported in

100 more than one study, and for which it was possible to identify duplicates, were described
101 only once, presenting the more detailed data. We identified duplicates based on author
102 names and hospital location, publication date, participant admission date, maternal and
103 neonatal characteristics and outcomes.

104 Doubts on possible duplicates and/or differences in the data extraction were discussed
105 and resolved by consensus, involving a third researcher (CR) whenever necessary.

106

107

112 **Results**

113 Table 1 summarizes the main characteristics of the 212 reported cases of pregnant women
114 diagnosed with COVID-19 and identified in 30 original studies published until April 8,
115 2020. A detailed description of each reported case is presented in Table S1 (supplemental
116 material).

117 All published cases occurred in China, except eight from the United States of America,¹¹,
118 ¹² one from South Korea,¹³ one from Honduras,¹⁴ one from Turkey,¹⁵ and another from
119 Sweden.¹⁶ Maternal age ranged from 22 to 41 years. From the 212 pregnant women
120 described, 182 delivered and 30 were discharged during pregnancy (undelivered). Most
121 women were in the third trimester of pregnancy and there was only one study reporting
122 pregnant women in the first trimester.¹⁷

123

124 **Vertical transmission of COVID-19**

125 All cases in which amniotic fluid, placenta, and/or cord blood were analyzed for SARS-
126 CoV-2 virus were negative.^{5, 11, 13, 15, 18-26}

127 Most studies detected the SARS-CoV-2 RNA by real-time reverse transcription-
128 polymerase chain reaction (RT-PCR) using samples from the newborn's nasopharyngeal

129 or throat, sample collection varying from immediately to 9 days after birth. Two studies
130 also used maternal and neonatal sera samples to test for IgG and IgM antibodies.^{27, 28}
131 Four newborns (2.2%) presented positive oral swabs for SARS-CoV-2.^{21, 24, 25, 29} In a
132 cohort of 33 newborns from mothers with COVID-19, admitted to the Pediatric Hospital
133 of Wuhan, three of the newborns had positive RT-PCR for SARS-CoV-2 in
134 nasopharyngeal and anal swabs collected on the second and fourth days after delivery,
135 with negative results on the sixth day for two newborns and on the seventh day for
136 another. However, placenta, amniotic fluid, and cord blood samples were not analyzed.²⁹
137 There is yet another case of a newborn with a positive RT-PCR for SARS COV-2 in one
138 throat swab collected at 36 hours after birth.^{21, 24} However, it was not possible to confirm
139 whether it was a real case of intrauterine transmission since the umbilical cord and
140 placenta blood samples were negative for SARS-CoV-2 and the possibility of postnatal
141 contact could not be discarded.^{21, 24} No other study reported positive results for the SARS-
142 CoV-2 virus in nasopharyngeal exudates from newborns of mothers diagnosed with
143 COVID-19.^{5, 11-20, 22-26, 29-36}
144 In a series of six cases that had blood collected after delivery evaluated, two of the
145 newborns had high levels of IgG and IgM antibodies (>10 AU/mL) and three had high
146 values of IgG antibodies with normal levels of IgM in, but in none SARS-CoV-2 virus
147 was detected by RT-PCR in the oropharyngeal exudate.²⁷ A case study also reported high
148 values of IgM and IgG antibodies in the blood at days 1 and 15 after delivery, but with
149 RT-PCR for SARS-CoV-2 negative in five samples of nasopharyngeal exudates collected
150 between the first two hours and the 16th day of life.²⁸
151 Seven studies reported the test of breast milk samples from 13 mothers and none
152 evidenced SARS-CoV-2 virus.^{5, 15, 16, 20-22, 28}
153

154 **Maternal and neonatal outcomes**

155 The clinical and obstetric conditions most frequently reported were fetal distress (n=20),
156 gestational diabetes (n=13), gestational hypertension (n=11), premature rupture of
157 membranes (PROM) (n=7), anemia (n=5), placenta previa/bleeding in the third trimester
158 (n=5), pre-eclampsia (n=4), hypothyroidism (n=4), chronic hypertension (n=3),
159 thalassemia(n=2), polycystic ovary syndrome (n=2), cholecystitis (n=2), asthma (n=2),
160 diabetes mellitus type 2 (n=2), placental abruption (n=1), oligohydramnios(n=1),
161 polyhydramnios (n=1), hepatitis B infection (n=1) and mitral valve and tricuspid valve
162 replacement (n=1). In one study that compared groups of pregnant women with and
163 without COVID-19, there were no significant differences in the occurrence of gestational
164 diabetes, severe pre-eclampsia, PROM, fetal distress, meconium-stained amniotic fluid,
165 premature delivery, neonatal asphyxia and procedures for severe post-partum bleeding.³⁰
166 Cesarean section was the most common type of delivery: 88.0% of 158 cases with
167 available information. Most studies did not specify the indication for the cesarean section.
168 Four pregnant women with severe COVID-19 required admission to an intensive care
169 unit: one at 30 weeks of gestation, after an emergency cesarean section;¹⁹ another case at
170 34 weeks of gestation that resulted in an emergency cesarean for a stillbirth;³¹ and other
171 two cases at 37 weeks of gestation of women with high BMI (>35) and history of medical
172 complications, admitted for labor induction.¹² No maternal deaths from COVID-19 were
173 published.

174 The 182 deliveries resulted in one stillbirth (intrauterine fetal death)³¹ and 185 live births
175 (four twin pregnancies). There was one neonatal death in a preterm infant (34 completed
176 weeks of gestation) from a pregnant woman with vaginal bleeding in the third trimester.¹⁸
177 Preterm birth occurred in 28.7% (45/157) among those with available information on
178 gestational age. Approximately 16% of preterm births were spontaneous due to PROM⁵.

179 18, 29, 31, 36 or spontaneous onset of labor,¹⁴ but in most cases, it is unclear whether these
180 were spontaneous or iatrogenic.

181 Although all breast milk samples from COVID-19 infected mothers have tested negative
182 for the SARS-CoV-2 virus, most infants did not receive breast milk.

183

184 **Discussion**

185 There is no evidence that the risk of infection with COVID-19 in pregnant women is
186 greater than in the general population.^{7, 37} However, the incidence of infection in pregnant
187 women is unknown, as screening tests were not generally used, except in the presence of
188 symptoms. In a New York's hospital that implemented universal SARS-CoV-2 testing in
189 all pregnant women admitted for delivery, 15.4% of them were positive for SARS-CoV-
190 2, but 87.9% were asymptomatic.³⁸

191 Although most of the published cases confirm the absence of transmission of the SARS-
192 CoV-2 virus antenatally or intrapartum, at least when the infection occurs in the third
193 trimester of pregnancy,^{5, 11, 13, 15, 18-26} emerging evidence has suggested that vertical
194 transmission is possible.^{21, 24, 25, 27-29} However, the evidence is still limited to a reduced
195 number of reported cases, large variability in the type of biological material analyzed and
196 the time of its collection. Even if vertical transmission occurred in the reported cases, the
197 proportion would be low, below 5% of the published cases.

198 Regarding the effect of the SARS-CoV-2 virus on the fetus, no congenital malformation
199 has been reported so far and the association of COVID-19 and fetal malformation seems
200 unlikely considering the reduced risk of intrauterine infection.³⁷

201 Higher risk of fetal distress and preterm births have been reported, but it is unclear if
202 preterm birth occurs spontaneously (spontaneous onset of labor or following PROM) or
203 is iatrogenic. The evidence related to the effect of COVID-19 on pregnant women is still

204 limited. The clinical characteristics of COVID-19 were similar to those described in non-
205 pregnant women, suggesting that the prognosis is not worse in pregnant women, although
206 the number of cases studied is still reduced.^{5, 18, 31-34} A recent systematic review
207 summarized the clinical manifestations of 108 pregnant women confirmed with COVID-
208 19 and most of them presented fever (68%) and coughing (34%), and lymphocytopenia
209 (59%) with elevated C-reactive protein (70%).³⁹

210 The maternal and neonatal outcomes observed so far are quite different from the two most
211 serious coronavirus-related previous epidemics.^{7, 40-53} The first also appeared in China, in
212 2002-03, and was characterized by severe respiratory infections caused by the Severe
213 Acute Respiratory Syndrome-Coronavirus (SARS-CoV). The second occurred in 2012,
214 initially in the Middle East, the Middle East Respiratory Syndrome - Coronavirus
215 (MERS-CoV).^{7, 40} These epidemics have demonstrated the ability of coronavirus to cause
216 serious complications during pregnancy,^{43, 53} with worse prognosis in pregnant women
217 than non-pregnant women.^{42, 54}

218 In the 2002 epidemic, 12 pregnant women were infected with SARS-CoV, with a fatality
219 rate of 25%.⁵³ Among the seven pregnant women infected in the first trimester, four had
220 a miscarriage.⁵³ Two of the five pregnant women infected during the second or third
221 trimester had fetal growth restriction and four had a preterm delivery (one spontaneous;
222 three induced by the maternal condition).⁵³ In a review of the pregnancy outcomes of 11
223 women infected with MERS-CoV, seven pregnant women required admission to the
224 intensive care unit and three died, of which only one had one comorbidity (asthma). Two
225 fetal deaths occurred, and three of nine newborns were preterm.⁴³

226 However, considering that SARS-CoV-2 has genetic homology and some clinical
227 similarities to SARS-CoV and MERS-CoV, and the immunological and physiological
228 changes that occur during pregnancy, such as in cell-mediated immunity or lung function,

229 that affect both the susceptibility and the clinical severity of pneumonia, it is important
230 to pay particular attention to the monitoring of pregnant women with COVID-19, because
231 maternal and perinatal adverse outcomes are potentially relevant.^{7, 40} Although there were
232 no maternal deaths described, possible maternal deaths were reported in social media, but
233 without any robust evidence.³⁷ Furthermore, one study reported two asymptomatic
234 pregnant women at admission for delivery that rapidly evolved to severe COVID-19
235 disease requiring admission to an intensive care unit.¹²

236 Thus, it is essential to prevent the infection of COVID-19 and any other viral respiratory
237 infection, as these infections represent an increased risk for the pregnant woman and for
238 the pregnancy itself.^{7, 55, 56} It is therefore extremely important that pregnant women adopt
239 preventive actions for COVID-19 with great intensity.³⁷ For pregnant women with
240 suspected or confirmed infection with SARS-CoV-2, recommendations for health
241 professionals and services have already been published.^{37, 55, 57-59}

242 Most women in this review had a cesarean section, many of them without a clear medical
243 indication. The decision on the type of delivery in pregnant women with suspected or
244 confirmed infection with COVID-19 should take into account the maternal and fetal
245 clinical characteristics, as in normal practice, and not the diagnosis of COVID-19
246 infection per se. Thus, there is no obstetric contraindication to any mode of delivery,
247 unless the pregnant woman's clinical condition implies an emergent decision.³⁷

248 In Portugal, we can estimate that about 80,000 pregnant women are exposed to the
249 pandemic at different gestational ages, which represents an important challenge for
250 individual and public health, to avoid infection in this population that should be
251 considered at higher risk. According to the information reported by health professionals,
252 there were eight cases of COVID-19 positive women delivered in Portugal by the 31st of
253 March 2020. None of the first eight infants (all live births) born in Portugal tested positive

254 for the SARS-CoV-2. Preterm birth occurred in 25% (2/8) of them and 5 (62.5%) resulted
255 in cesarean section.

256 The limited scientific knowledge currently available makes it difficult to develop specific
257 breastfeeding recommendations. There is not enough scientific evidence to unequivocally
258 state that there is no possibility that mothers with COVID-19 can transmit the virus
259 through breast milk.⁵⁵ Therefore, recommendations should be based on the available data
260 ^{5, 15, 16, 20-22, 28} and the analogy with past circumstances and predictable costs and benefits.

261 Breastfeeding is recognized as the best form of child feeding due to the countless benefits
262 for both the mother and the newborn, including the protection against gastrointestinal and
263 respiratory infections.⁶⁰ Thus, considering the benefits of breastfeeding and the fact that
264 the transmission of other respiratory viruses is insignificant through breast milk, there is
265 no indication to stop breastfeeding. According to the recommendations of
266 WHO/UNICEF⁶¹ and the Center for Disease Control and Prevention (CDC) of the United
267 States,⁵⁵ women with suspected or confirmed infection with COVID-19 can initiate or
268 continue breastfeeding as long as clinical conditions permit. The CDC indicates that the
269 decision to initiate or continue breastfeeding must be determined by the mother with
270 COVID-19, together with family members and health professionals.⁵⁵

271 Limitations of this systematic review should be acknowledged. Considerable
272 heterogeneity was observed across the studies, which did not allow us to conduct a meta-
273 analysis. On the other hand, we cannot guarantee that we were able to identify all the
274 cases of pregnant women described in the literature. Possibly there are additional cases
275 currently presented in other types of publications, such as reports. Also, considering the
276 importance of summarizing all existing cases, we did not assess the quality of the studies
277 included in this review. Several studies had missing outcome data and selective reporting
278 bias could not be excluded. Additionally, there may be some cases which could be

279 duplicated, namely the studies which did not describe clinical characteristics case by
280 case.^{30, 33, 34, 36}

281

282 **Conclusion**

283 According to this review, fetal distress and preterm delivery seem to be more frequent
284 among pregnant women with COVID-19. There is emerging evidence on possible vertical
285 transmission (four positive results in the neonatal oral swabs for SARS-CoV-2 were
286 reported and three newborns had high values of IgM antibodies), but the clinical relevance
287 of the fetal infection is unclear. So far, there is no evidence that the SARS-CoV-2 virus
288 is transmitted through breast milk. Maternal deaths were not reported and hospitalizations
289 in intensive care were uncommon. Although the complications appear to be similar to
290 those of non-pregnant women, services must be prepared to attend to complications,
291 especially in pregnant women with comorbidities. Therefore, pregnant women and
292 newborns should be considered particularly vulnerable populations regarding COVID-19
293 prevention and management strategies. Information, counseling and adequate monitoring
294 are essential to prevent major adverse effects of SARS-CoV-2 infection during
295 pregnancy.

312 **Acknowledgments**

313 The authors are grateful to the health professionals who provided and confirmed the cases
314 of pregnant women diagnosed with COVID-19 in Portugal: Alcides Pereira, Alexandra
315 Almeida, Alexandrina Portela, Almerinda Pereira, Anselmo Costa, Gabriela Mimoso,
316 Pedro Vieira da Silva, Rosalina Barroso, Teresa Rodrigues, Teresa Tomé.

317

318 **Disclosure statement**

319 The authors report no conflict of interest.

320

321 **Funding**

322 This study was funded by national funding from the Foundation for Science
323 and Technology – FCT (Portuguese Ministry of Science, Technology and Higher
324 Education), the Operational Programmes Competitiveness and Internationalization
325 (COMPETE 2020) and Human Capital (POCH), Portugal 2020, under the Unidade de
326 Investigação em Epidemiologia - Instituto de Saúde Pública da Universidade do Porto
327 (EPIUnit) (POCI-01-0145-FEDER-006862; UID/DTP/04750/2019) and the PhD grant
328 SFRH/BD/111794/2015 (CR).

329

330 **Ethics approval**

331 This study is a systematic review based on published studies; therefore, ethical approval
332 was not required.

333

334 **Authors' contributions**

- 335 Carina Rodrigues and Henrique Barros: Conceptualization, Original draft preparation.
- 336 Inês Baía and Rosa Domingues: Methodology, Data curation, Writing-Reviewing, and
- 337 Editing. All authors read and approved the final manuscript.

338 **References**

339

- 340 1. Hui SD, Azhar EI, Madani TA, et al. The continuing 2019-nCoV epidemic
341 threat of novel coronaviruses to global health - The latest 2019 novel
342 coronavirus outbreak in Wuhan, China. *Int J Infect Dis* 2020;91:264-66.
- 343 2. Caldas JP, Tavares M. *Epidemiologia da COVID-19*. 2020. [Internet]. [cited
344 2020 Apr 13] Available from:
345 [http://asset.youoncdn.com/ab296ab30c207ac641882479782c6c34/070b44658f5](http://asset.youoncdn.com/ab296ab30c207ac641882479782c6c34/070b44658f5569888804a14826ae273c.pdf)
346 [569888804a14826ae273c.pdf](http://asset.youoncdn.com/ab296ab30c207ac641882479782c6c34/070b44658f5569888804a14826ae273c.pdf)
- 347 3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of
348 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive
349 study. *Lancet* 2020;395:507-13.
- 350 4. Russell TW, Hellewell J, Jarvis CI, et al. Estimating the infection and case
351 fatality ratio for COVID-19 using age-adjusted data from the outbreak on the
352 Diamond Princess cruise ship. *MedRxiv* 2020:2020.03.05.20031773.
- 353 5. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical
354 transmission potential of COVID-19 infection in nine pregnant women: a
355 retrospective review of medical records. *Lancet* 2020.
- 356 6. Qiao J. What are the risks of COVID-19 infection in pregnant women? *Lancet*
357 2020.
- 358 7. Rasmussen SA, Smulian JC, Lednicky JA, Wen TS, Jamieson DJ. Coronavirus
359 Disease 2019 (COVID-19) and Pregnancy: What obstetricians need to know. *Am*
360 *J Obstet Gynecol* 2020.
- 361 8. Favre G, Pomar L, Musso D, Baud D. 2019-nCoV epidemic: what about
362 pregnancies? *Lancet* 2020;395:e40.

- 363 9. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting
364 systematic reviews and meta-analyses of studies that evaluate health care
365 interventions: explanation and elaboration. *PLoS Med* 2009;6:e1000100.
- 366 10. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic
367 review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev*
368 2015;4:1.
- 369 11. Iqbal SN, Overcash R, Mokhtari N, et al. An Uncomplicated Delivery in a
370 Patient with Covid-19 in the United States. *N Engl J Med* 2020.
- 371 12. Breslin N, Baptiste C, Miller R, et al. COVID-19 in pregnancy: early lessons.
372 *Am J Obstet Gynecol* 2020:100111.
- 373 13. Lee DH, Lee J, Kim E, Woo K, Park HY, An J. Emergency cesarean section on
374 severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) confirmed
375 patient. *Korean J Anesthesiol* 2020.
- 376 14. Zambrano LI, Fuentes-Barahona IC, Bejarano-Torres DA, et al. A pregnant
377 woman with COVID-19 in Central America. *Travel Med Infect Dis*
378 2020:101639.
- 379 15. Kalafat E, Yaprak E, Cinar G, et al. Lung ultrasound and computed tomographic
380 findings in pregnant woman with COVID-19. *Ultrasound Obstet Gynecol* 2020.
- 381 16. Gidlöf S, Savchenko J, Brune T, Josefsson H. COVID-19 in pregnancy with
382 comorbidities: More liberal testing strategy is needed. *Acta Obstet Gynecol*
383 *Scand* 2020.
- 384 17. Liu D, Li L, Wu X, et al. Pregnancy and Perinatal Outcomes of Women With
385 Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis. *AJR Am*
386 *J Roentgenol* 2020:1-6.

- 387 18. Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 neonates born to mothers
388 with 2019-nCoV pneumonia. *Transl Pediatr* 2020;9:51-60.
- 389 19. Wang X, Zhou Z, Zhang J, Zhu F, Tang Y, Shen X. A case of 2019 Novel
390 Coronavirus in a pregnant woman with preterm delivery. *Clin Infect Dis* 2020.
- 391 20. Li Y, Zhao R, Zheng S, et al. Lack of Vertical Transmission of Severe Acute
392 Respiratory Syndrome Coronavirus 2, China. *Emerg Infect Dis* 2020;26.
- 393 21. Wang S, Guo L, Chen L, et al. A case report of neonatal COVID-19 infection in
394 China. *Clin Infect Dis* 2020.
- 395 22. Fan C, Lei D, Fang C, et al. Perinatal Transmission of COVID-19 Associated
396 SARS-CoV-2: Should We Worry? *Clin Infect Dis* 2020.
- 397 23. Liao X, Yang H, Kong J, Yang H. Chest CT Findings in a Pregnant Patient with
398 2019 Novel Coronavirus Disease. *Balkan Med J* 2020.
- 399 24. Yu N, Li W, Kang Q, et al. Clinical features and obstetric and neonatal
400 outcomes of pregnant patients with COVID-19 in Wuhan, China: a
401 retrospective, single-centre, descriptive study. *Lancet Infect Dis* 2020.
- 402 25. Liu W, Wang Q, Zhang Q, et al. Coronavirus Disease 2019 (COVID-19) During
403 Pregnancy: A Case Series. *Preprints* 2020.
- 404 26. Chen S, Huang B, Luo DJ, et al. [Pregnant women with new coronavirus
405 infection: a clinical characteristics and placental pathological analysis of three
406 cases]. *Zhonghua Bing Li Xue Za Zhi* 2020;49:E005.
- 407 27. Zeng H, Xu C, Fan J, et al. Antibodies in Infants Born to Mothers With COVID-
408 19 Pneumonia. *JAMA* 2020.
- 409 28. Dong L, Tian J, He S, et al. Possible Vertical Transmission of SARS-CoV-2
410 From an Infected Mother to Her Newborn. *JAMA* 2020.

- 411 29. Zeng L, Xia S, Yuan W, et al. Neonatal Early-Onset Infection With SARS-CoV-
412 2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China. *JAMA*
413 *Pediatr* 2020.
- 414 30. Zhang L, Jiang Y, Wei M, et al. [Analysis of the pregnancy outcomes in
415 pregnant women with COVID-19 in Hubei Province]. *Zhonghua Fu Chan Ke Za*
416 *Zhi* 2020;55:E009.
- 417 31. Liu Y, Chen H, Tang K, Guo Y. Clinical manifestations and outcome of SARS-
418 CoV-2 infection during pregnancy. *J Infect* 2020.
- 419 32. Chen S, Liao E, Shao Y. Clinical analysis of pregnant women with 2019 novel
420 coronavirus pneumonia. *J Med Virol* 2020.
- 421 33. Chen R, Zhang Y, Huang L, Cheng BH, Xia ZY, Meng QT. Safety and efficacy
422 of different anesthetic regimens for parturients with COVID-19 undergoing
423 Cesarean delivery: a case series of 17 patients. *Can J Anaesth* 2020.
- 424 34. Liu H, Liu F, Li J, Zhang T, Wang D, Lan W. Clinical and CT imaging features
425 of the COVID-19 pneumonia: Focus on pregnant women and children. *J Infect*
426 2020.
- 427 35. Xia H, Zhao S, Wu Z, Luo H, Zhou C, Chen X. Emergency Caesarean delivery
428 in a patient with confirmed coronavirus disease 2019 under spinal anaesthesia.
429 *Br J Anaesth* 2020.
- 430 36. Li N, Han L, Peng M, et al. Maternal and neonatal outcomes of pregnant women
431 with COVID-19 pneumonia: a case-control study. *MedRxiv*
432 2020:2020.03.10.20033605.
- 433 37. Royal College of Obstetricians and Gynaecologists, Royal College of Midwives,
434 Royal College of Paediatrics and Child Health, Public Health England and
435 Health Protection Scotland (2020). *Coronavirus (COVID-19) Infection in*

- 436 *Pregnancy: Information for healthcare professionals (Version 8)*. [Internet].
437 [cited 2020 Apr 9] Available from:
438 [https://www.rcog.org.uk/globalassets/documents/guidelines/2020-04-17-](https://www.rcog.org.uk/globalassets/documents/guidelines/2020-04-17-coronavirus-covid-19-infection-in-pregnancy.pdf)
439 [coronavirus-covid-19-infection-in-pregnancy.pdf](https://www.rcog.org.uk/globalassets/documents/guidelines/2020-04-17-coronavirus-covid-19-infection-in-pregnancy.pdf)
- 440 38. Sutton D, Fuchs K, D'Alton M, Goffman D. Universal Screening for SARS-
441 CoV-2 in Women Admitted for Delivery. *N Engl J Med* 2020.
- 442 39. Zaigham M, Andersson O. Maternal and Perinatal Outcomes with COVID-19: a
443 systematic review of 108 pregnancies. *Acta Obstet Gynecol Scand* 2020.
- 444 40. Schwartz DA, Graham AL. Potential Maternal and Infant Outcomes from
445 (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from
446 SARS, MERS, and Other Human Coronavirus Infections. *Viruses* 2020;12.
- 447 41. Stockman LJ, Lowther SA, Coy K, Saw J, Parashar UD. SARS during
448 pregnancy, United States. *Emerg Infect Dis* 2004;10:1689-90.
- 449 42. Maxwell C, McGeer A, Tai KFY, Sermer M. No. 225-Management Guidelines
450 for Obstetric Patients and Neonates Born to Mothers With Suspected or
451 Probable Severe Acute Respiratory Syndrome (SARS). *J Obstet Gynaecol Can*
452 2017;39:e130-e37.
- 453 43. Alfaraj SH, Al-Tawfiq JA, Memish ZA. Middle East Respiratory Syndrome
454 Coronavirus (MERS-CoV) infection during pregnancy: Report of two cases &
455 review of the literature. *J Microbiol Immunol Infect* 2019;52:501-03.
- 456 44. Alserehi H, Wali G, Alshukairi A, Alraddadi B. Impact of Middle East
457 Respiratory Syndrome coronavirus (MERS-CoV) on pregnancy and perinatal
458 outcome. *BMC Infect Dis* 2016;16:105.

- 459 45. Assiri A, Abedi GR, Al Masri M, Bin Saeed A, Gerber SI, Watson JT. Middle
460 East Respiratory Syndrome Coronavirus Infection During Pregnancy: A Report
461 of 5 Cases From Saudi Arabia. *Clin Infect Dis* 2016;63:951-53.
- 462 46. Haines CJ, Chu YW, Chung TK. The effect of Severe Acute Respiratory
463 Syndrome on a hospital obstetrics and gynaecology service. *BJOG*
464 2003;110:643-5.
- 465 47. Jeong SY, Sung SI, Sung JH, et al. MERS-CoV Infection in a Pregnant Woman
466 in Korea. *J Korean Med Sci* 2017;32:1717-20.
- 467 48. Jiang X, Gao X, Zheng H, et al. Specific immunoglobulin g antibody detected in
468 umbilical blood and amniotic fluid from a pregnant woman infected by the
469 coronavirus associated with severe acute respiratory syndrome. *Clin Diagn Lab*
470 *Immunol* 2004;11:1182-4.
- 471 49. Malik A, El Masry KM, Ravi M, Sayed F. Middle East Respiratory Syndrome
472 Coronavirus during Pregnancy, Abu Dhabi, United Arab Emirates, 2013. *Emerg*
473 *Infect Dis* 2016;22:515-7.
- 474 50. Owolabi T, Kwolek S. Managing obstetrical patients during severe acute
475 respiratory syndrome outbreak. *J Obstet Gynaecol Can* 2004;26:35-41.
- 476 51. Payne DC, Iblan I, Alqasrawi S, et al. Stillbirth during infection with Middle
477 East respiratory syndrome coronavirus. *J Infect Dis* 2014;209:1870-2.
- 478 52. Robertson CA, Lowther SA, Birch T, et al. SARS and pregnancy: a case report.
479 *Emerg Infect Dis* 2004;10:345-8.
- 480 53. Wong SF, Chow KM, Leung TN, et al. Pregnancy and perinatal outcomes of
481 women with severe acute respiratory syndrome. *Am J Obstet Gynecol*
482 2004;191:292-7.

- 483 54. Lam CM, Wong SF, Leung TN, et al. A case-controlled study comparing
484 clinical course and outcomes of pregnant and non-pregnant women with severe
485 acute respiratory syndrome. *BJOG* 2004;111:771-4.
- 486 55. Centers for Disease Control and Prevention (CDC). *Pregnancy & Breastfeeding:*
487 *Information about Coronavirus Disease 2019*. [Internet]. [cited 2020 Apr 9]
488 Available from:
489 [https://www.cdc.gov/coronavirus/2019-ncov/prepare/pregnancy-](https://www.cdc.gov/coronavirus/2019-ncov/prepare/pregnancy-breastfeeding.html)
490 [breastfeeding.html](https://www.cdc.gov/coronavirus/2019-ncov/prepare/pregnancy-breastfeeding.html)
- 491 56. Yang H, Wang C, Poon LC. Novel coronavirus infection and pregnancy.
492 *Ultrasound Obstet Gynecol* 2020.
- 493 57. Favre G, Pomar L, Qi X, Nielsen-Saines K, Musso D, Baud D. Guidelines for
494 pregnant women with suspected SARS-CoV-2 infection. *Lancet Infect Dis* 2020.
- 495 58. Poon LC, Yang H, Lee JCS, et al. ISUOG Interim Guidance on 2019 novel
496 coronavirus infection during pregnancy and puerperium: information for
497 healthcare professionals. *Ultrasound Obstet Gynecol* 2020.
- 498 59. Liang H, Acharya G. Novel corona virus disease (COVID-19) in pregnancy:
499 What clinical recommendations to follow? *Acta Obstet Gynecol Scand* 2020.
- 500 60. Victora CG, Bahl R, Barros AJ, et al. Breastfeeding in the 21st century:
501 epidemiology, mechanisms, and lifelong effect. *Lancet* 2016;387:475-90.
- 502 61. UNICEF/World Health Organization. *Coronavirus disease (COVID-19): What*
503 *parents should know*. [Internet]. [cited 2020 Apr 9] Available from:
504 <https://www.unicef.org/stories/novel-coronavirus-outbreak-what-parents-should-know>
- 505 62. Luo Y, Yin K. Management of pregnant women infected with COVID-19.
506 *Lancet Infect Dis* 2020.

- 507 63. Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically
508 ill patients with SARS-CoV-2 infection. *Chest* 2020.
- 509 64. Wen R, Sun Y, Xing QS. A patient with SARS-CoV-2 infection during
510 pregnancy in Qingdao, China. *J Microbiol Immunol Infect* 2020.

511 **Table 1. Characteristics of pregnant women diagnosed with COVID-19 described in**
 512 **the literature (n=212).**

513

	n/N (%)
Maternal characteristics	
Age, years (min-max)	22-43
Country of hospital admission	
China	200/212 (94.3)
United States of America	8/212 (3.8)
South Korea	1/212 (0.5)
Honduras	1/212 (0.5)
Turkey	1/212 (0.5)
Sweden	1/212 (0.5)
Pregnancy complications	
Fetal distress	20/212 (9.4)
Gestational diabetes	13/212 (6.1)
Gestational hypertension	11/212 (5.2)
PROM	7/212 (3.3)
Anemia	5/212 (2.4)
Placenta previa/bleeding	5/212 (2.4)
Preeclampsia	4/212 (1.9)
Hypothyroidism	4/212 (1.9)
Chronic hypertension	3/212 (1.4)
Thalassemia	2/212 (0.9)
Polycystic ovary syndrome	2/212 (0.9)
Cholecystitis	2/212 (0.9)
Asthma	2/212 (0.9)
Diabetes mellitus type 2	2/212 (0.9)
Placental abruption	1/212 (0.5)
Oligohydramnios	1/212 (0.5)
Polyhydramnios	1/212 (0.5)
Hepatitis B infection	1/212 (0.5)
Mitral valve and tricuspid valve replacement	1/212 (0.5)
Pregnancy characteristics/outcomes	
Pregnant women at discharge (undelivered)	30/212 (14.2)
Multiple pregnancies	4/212 (1.9)
Deliveries	182/212 (85.8)
Multiple pregnancies delivered	4/182 (2.2)
Stillbirths	1/186 (0.5)

Live births	185/186 (99.5)
Cesarean section	139/158 (88.0)
Preterm birth (<37 weeks of gestation)	45/157 (28.7)
Maternal outcomes	
Maternal deaths	0/212 (0.0)
Maternal admission to Intensive Care Unit	4/212 (1.9)
Neonatal outcomes	
Neonatal deaths	1/185 (0.5)
SARS-CoV-2 infection confirmed by oral swabs	4/185 (2.2)
High levels of SARS-CoV-2 IgM antibodies	3/185 (1.6)
Type of intrauterine/ neonatal samples collected and results	
Placenta	21/186 (11.3)
Positive results	0/21 (0.0)
Cord blood	13/186 (7.0)
Positive results	0/13 (0.0)
Amniotic fluid	14/186 (7.5)
Positive results	0/14 (0.0)
Newborn's oral swabs	70/185 (33.8)
Positive results	4/70 (5.7)
Measurement of SARS-CoV-2 IgM and IgG antibody	7/185 (3.8)
Reactive IgM	3/7 (42.8)
Reactive IgG	6/7 (85.7)
Breast milk	13/185 (7.0)
Positive results	0/13 (0.0)
